The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
Open accessAbstract
PURPOSE: Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resectable esophageal or junctional cancer. We aimed to assess long-term outcome of this regimen. METHODS: From 2004 through 2008, we randomly assigned 366 patients to either five weekly cycles of carboplatin and paclitaxel with concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week) followed by surgery, or surgery alone. Follow-up data were collected through 2018. Cox regression analyses were performed to compare overall survival, cause-specific survival, and risks of locoregional and distant relapse. The effect of neoadjuvant chemoradiotherapy beyond 5 years of follow-up was tested with time-dependent Cox regression and landmark analyses. RESULTS: The median follow-up was 147 months (interquartile range, 134-157). Patients receiving neoadjuvant chemoradiotherapy had better overall survival (hazard ratio [HR], 0.70; 95% CI, 0.55 to 0.89). The effect of neoadjuvant chemoradiotherapy on overall survival was not time-dependent ( P value for interaction, P = .73), and landmark analyses suggested a stable effect on overall survival up to 10 years of follow-up. The absolute 10-year overall survival benefit was 13% (38% v 25%). Neoadjuvant chemoradiotherapy reduced risk of death from esophageal cancer (HR, 0.60; 95% CI, 0.46 to 0.80). Death from other causes was similar between study arms (HR, 1.17; 95% CI, 0.68 to 1.99). Although a clear effect on isolated locoregional (HR, 0.40; 95% CI, 0.21 to 0.72) and synchronous locoregional plus distant relapse (HR, 0.43; 95% CI, 0.26 to 0.72) persisted, isolated distant relapse was comparable (HR, 0.76; 95% CI, 0.52 to 1.13). CONCLUSION: The overall survival benefit of patients with locally advanced resectable esophageal or junctional cancer who receive preoperative chemoradiotherapy according to CROSS persists for at least 10 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
Cunningham, D., Allum, W. H., Stenning, S. P., Thompson, J. N., Van de Velde, C. J. H., Nicolson, M., Scarffe, J. H., Lofts, F. J., Falk, S. J., Iveson, T. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055531 · Cited by 6,334
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
van Hagen, P., Hulshof, M. C. C. M., van Lanschot, J. J. B., Steyerberg, E. W., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Richel, D. J., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112088 · Cited by 5,521
Self-citationRisk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974 · cited 2×
“Patients receiving radiotherapy to the chest are also at risk of late cardiopulmonary toxicity.(14,15) Within the CROSS trial, adverse events were not recorded after the initial 2-year report of the trial, potentially leading to underestimation of the toxicity of the CROSS regimen.”
BackgroundAl-Batran, S.-E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S., Kopp, H.-G., Mayer, F., Haag, G. M., Luley, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32557-1 · Cited by 2,648
Shapiro, J., van Lanschot, J. J. B., Hulshof, M. C. C. M., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00040-6 · Cited by 2,565
Self-citationA Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma
Walsh, T. N., Noonan, N., Hollywood, D., Kelly, A., Keeling, N., & Hennessy, T. P. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608153350702 · Cited by 1,950
van Gijn, W., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. M.-K., Putter, H., Wiggers, T., Rutten, H. J., Påhlman, L., Glimelius, B., & van de Velde, C. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70097-3 · Cited by 1,888
Ando, N., Kato, H., Igaki, H., Shinoda, M., Ozawa, S., Shimizu, H., Nakamura, T., Yabusaki, H., Aoyama, N., Kurita, A., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2049-9 · Cited by 1,427
Forastiere, A. A., Zhang, Q., Weber, R. S., Maor, M. H., Goepfert, H., Pajak, T. F., Morrison, W., Glisson, B., Trotti, A., Ridge, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.6097 · Cited by 1,296
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lordick, F., Mariette, C., Haustermans, K., Obermannová, R., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw329 · Cited by 1,098
Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G., Untch, M., Smith, I., Gianni, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32616-2 · Cited by 1,035
Allum, W. H., Stenning, S. P., Bancewicz, J., Clark, P. I., & Langley, R. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2083 · Cited by 989
André, T., de Gramont, A., Vernerey, D., Chibaudel, B., Bonnetain, F., Tijeras-Raballand, A., Scriva, A., Hickish, T., Tabernero, J., Van Laethem, J. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4238 · Cited by 683
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Kitagawa, Y., Uno, T., Oyama, T., Kato, K., Kato, H., Kawakubo, H., Kawamura, O., Kusano, M., Kuwano, H., Takeuchi, H., et al. (2019) · Esophagus · doi:10.1007/s10388-018-0641-9 · Cited by 519
Ishikura, S., Nihei, K., Ohtsu, A., Boku, N., Hironaka, S., Mera, K., Muto, M., Ogino, T., & Yoshida, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.055 · Cited by 373
Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline
Shah, M. A., Kennedy, E. B., Catenacci, D. V., Deighton, D. C., Goodman, K. A., Malhotra, N. K., Willett, C., Stiles, B., Sharma, P., Tang, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00866 · Cited by 333
Self-citationCompeting risks and the clinical community: irrelevance or ignorance?
Koller, M. T., Raatz, H., Steyerberg, E. W., & Wolbers, M. (2012) · Statistics in Medicine · doi:10.1002/sim.4384 · Cited by 302
Self-citationNakamura, K., Kato, K., Igaki, H., Ito, Y., Mizusawa, J., Ando, N., Udagawa, H., Tsubosa, Y., Daiko, H., Hironaka, S., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt061 · Cited by 289
Reynolds, J. V., Preston, S. R., O’Neill, B., Bæksgaard, L., Griffin, S. M., Mariette, C., Cuffe, S. D., Cunningham, M. S., Crosby, T., Parker, I., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3386-2 · Cited by 162
Noordman, B. J., Verdam, M. G. E., Lagarde, S. M., Hulshof, M. C. C. M., van Hagen, P., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7718 · Cited by 131
Self-citationXi, M., Yang, Y., Zhang, L., Yang, H., Merrell, K. W., Hallemeier, C. L., Shen, R. K., Haddock, M. G., Hofstetter, W. L., Maru, D. M., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002670 · Cited by 101
Noordman, B. J., Verdam, M. G. E., Lagarde, S. M., Shapiro, J., Hulshof, M. C. C. M., Henegouwen, M. I. V. B., Wijnhoven, B. P. L., Nieuwenhuijzen, G. A. P., Bonenkamp, J. J., Cuesta, M. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx726 · Cited by 85
Self-citationStroes, C. I., Schokker, S., Creemers, A., Molenaar, R. J., Hulshof, M. C. C. M., van der Woude, S. O., Bennink, R. J., Mathôt, R. A. A., Krishnadath, K. K., Punt, C. J. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01814 · Cited by 74
Self-citationBlackham, A. U., Naqvi, S. M. H., Schell, M. J., Jin, W. H., Gangi, A., Almhanna, K., Fontaine, J. P., Hoffe, S. E., Frakes, J. M., Venkat, P. S., et al. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24808 · Cited by 27
Cited by
Yang, H., Wang, F., Hallemeier, C. L., Lerut, T., & Fu, J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02226-8 · Cited by 299
Kato, K., Machida, R., Ito, Y., Daiko, H., Ozawa, S., Ogata, T., Hara, H., Kojima, T., Abe, T., Bamba, T., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00745-1 · Cited by 280
Metadata
- Authors
- Eyck, B. M., van Lanschot, J. J. B., Hulshof, M. C. C. M., van der Wilk, B. J., Shapiro, J., van Hagen, P., van Berge Henegouwen, M. I., Wijnhoven, B. P. L., van Laarhoven, H. W. M., Nieuwenhuijzen, G. A. P., Hospers, G. A. P., Bonenkamp, J. J., Cuesta, M. A., Blaisse, R. J. B., Busch, O. R., Creemers, G.-J. M., Punt, C. J. A., Plukker, J. T. M., Verheul, H. M. W., Spillenaar Bilgen, E. J., van der Sangen, M. J. C., Rozema, T., ten Kate, F. J. W., Beukema, J. C., Piet, A. H. M., van Rij, C. M., Reinders, J. G., Tilanus, H. W., Steyerberg, E. W., van der Gaast, A., & for the CROSS Study Group
- Venue
- Journal of Clinical Oncology
- Published
- 2021-06-20
- Volume
- 39
- Issue
- 18
- Pages
- 1995-2004
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3154482193
- Cited by
- 795
- References
- 24
- FWCI
- 99.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.